Practical approaches to male hypogonadism in Australian care
Male hypogonadism describes a clinical syndrome in which the testes fail to produce adequate testosterone, accompanied by characteristic signs ranging from low libido and fatigue to reduced muscle mass and changes in mood. The condition affects an estimated one in every twenty men over forty, with prevalence rising steadily into older age groups. Because symptoms overlap with many common complaints in primary care, the disorder is frequently under-recognised, particularly when men present with non-specific tiredness or weight gain rather than sexual dysfunction.
In Australia, the demographic shift toward an older population means that clinicians in cities such as Sydney, Melbourne, Brisbane, and Perth are seeing more men with overlapping urological and endocrine concerns. Referral pathways commonly move through general practitioners, who order initial pathology, to urologists or endocrinologists who manage complex cases. Awareness campaigns from Healthy Male (formerly Andrology Australia) have improved public recognition of androgen deficiency, but gaps remain, particularly among men from culturally and linguistically diverse backgrounds who may attribute symptoms to ageing or stress.
Local practice is shaped by the Therapeutic Goods Administration, the Pharmaceutical Benefits Scheme for testosterone products, and Medicare-funded pathology testing. Many clinicians follow consensus statements from the Endocrine Society of Australia alongside broader international guidance adapted for Australian regulatory realities. These resources help to standardise testosterone interpretation, identify which men warrant further investigation, and determine when pharmacological therapy is appropriate.
This article outlines the diagnostic workup that confirms androgen deficiency, examines the treatment options available on Australian formularies, and discusses monitoring strategies that balance benefits with cardiovascular and prostate risks. It also touches on fertility-sparing approaches and the role of lifestyle modification within a comprehensive management plan.
Recognising symptoms and initial presentation in primary care
The clinical picture of androgen deficiency varies considerably across age groups and comorbidities. Younger men with primary testicular failure typically present with overt features such as gynaecomastia, small testicular volume, and infertility, while older men with secondary causes often describe insidious fatigue, reduced exercise tolerance, and erectile difficulties initially attributed to lifestyle factors.
For men over fifty, the symptom complex frequently overlaps with lower urinary tract symptoms from benign prostatic enlargement, which is why a structured assessment addressing both issues is essential. Readers can find parallel guidance on BPH symptom management elsewhere on this site. In women, chronic pelvic discomfort can mimic some urological complaints, and current approaches to treating bladder pain syndrome offer useful differential context for clinicians weighing overlapping presentations.
Confirming the biochemical diagnosis with laboratory testing
A single low morning testosterone level is not enough to confirm the diagnosis. The Endocrine Society of Australia recommends two separate morning samples, drawn before 10 a.m. and processed by a reliable assay, before pursuing treatment. Laboratories around the country use a mix of mass spectrometry and immunoassay platforms, and clinicians should understand the reference range reported by their local provider rather than relying on a universal cutoff.
Several pre-analytical factors influence results. Acute illness, recent alcohol intake, opioid medications, and severe sleep deprivation can transiently suppress testosterone. SHBG should be measured in parallel because conditions such as hyperthyroidism, obesity, and ageing alter binding protein concentrations and affect calculated free testosterone. Calculating free testosterone with the Vermeulen equation or measuring it directly through equilibrium dialysis both have roles in equivocal cases.
Repeat testing should always occur before committing a patient to long-term therapy. Men whose values fall in the lower third of the reference range warrant closer follow-up, even when formal thresholds are not yet reached.
Differentiating primary from secondary hypogonadism
Once biochemical deficiency is confirmed, identifying the source of the problem guides subsequent management. LH and FSH distinguish primary testicular failure from hypothalamic-pituitary causes. Markedly elevated gonadotrophins with low testosterone indicate primary hypogonadism, while low or inappropriately normal gonadotrophins suggest a central problem requiring pituitary imaging and prolactin measurement.
Prolactin elevation warrants MRI of the pituitary to exclude adenoma or other infiltrative disease. Men with Kallmann syndrome, history of anabolic steroid use, or opioid dependence commonly present with secondary patterns. Patients with chronic conditions such as type 2 diabetes or obesity often have mixed pictures, and treatment decisions must consider whether weight loss or management of the underlying disorder might restore endogenous production before initiating replacement.
Hypogonadism classification also has implications for treatment. Men with secondary causes may benefit from treating the underlying disorder before replacement, while those with primary testicular failure usually require lifelong testosterone therapy. Genetic testing is increasingly used in younger men with persistent low testosterone, particularly when congenital causes such as Klinefelter syndrome are suspected.
Testosterone replacement options available in Australia
Several formulations are listed on the Pharmaceutical Benefits Scheme or available through private prescription. Choice depends on patient preference, cost, frequency of administration, and whether fertility preservation is desired. The table below compares the main preparations encountered in Australian practice.
| Formulation | Brand examples | Dosing frequency | PBS availability | Key considerations |
|---|---|---|---|---|
| Long-acting intramuscular | Reandron | Every 10–14 weeks | Yes | Stable trough levels; requires clinic-based deep injection |
| Short-acting intramuscular | Sustanon (private) | Every 2–4 weeks | Limited | Peaks and troughs may cause mood swings; lower upfront cost |
| Transdermal gel | Androgel, Testogel | Daily | Restricted | Skin-to-skin transfer risk; suits men preferring self-administration |
| Buccal patch | Striant | Twice daily | No | Less commonly prescribed domestically |
| Subcutaneous pellets | Testopel (compounded) | Every 3–6 months | No | Minor surgical procedure; limited availability |
For men whose primary concern is maintaining fertility, testosterone replacement is contraindicated because exogenous androgens suppress spermatogenesis. Pulsatile GnRH or gonadotrophin therapy with hCG and FSH can be pursued through reproductive endocrinology units in Brisbane, Sydney, and Melbourne.
The choice of formulation has practical implications for adherence. Men who dislike needles often prefer daily gels, while those seeking infrequent dosing appreciate long-acting injections. Cost also matters; Reandron is subsidised on the PBS, whereas gels and pellets typically require private payment. Discussing these practicalities upfront improves long-term satisfaction and persistence with treatment.
Monitoring therapy and cardiovascular considerations
Once treatment starts, structured follow-up is essential. The Australian consensus recommends clinical review at three and six months, with measurement of trough testosterone, haematocrit, liver function, and PSA. Haematocrit above 54 percent warrants dose reduction, switching delivery method, or therapeutic phlebotomy. Cardiovascular risk factors should be reassessed annually because testosterone can affect lipid profiles and blood pressure.
In older men with atrial fibrillation or other rhythm disturbances, the choice of anticoagulation during planned procedures deserves careful consideration, and the interrupted versus uninterrupted discussion from a recent arrhythmia publication offers relevant context. Polypharmacy is common in this cohort, and clinicians should review interactions with warfarin, direct oral anticoagulants, and opioid analgesics.
Prostate monitoring is another cornerstone of safe treatment. Baseline digital rectal examination and PSA should be recorded before starting therapy. Subsequent rises in PSA greater than 1.4 nanograms per millilitre over twelve months warrant urological review, and any suspicion of prostate cancer should be investigated before continuing replacement. These precautions reflect Australian recommendations that align with international guidance.
Fertility-sparing alternatives and hormonal modulation
For men under fifty who wish to preserve fertility, options include human chorionic gonadotrophin to stimulate intratesticular testosterone, selective oestrogen receptor modulators such as clomiphene, and aromatase inhibitors such as anastrozole. These agents raise endogenous production without suppressing spermatogenesis, though evidence varies by indication. Referral to a reproductive specialist is advisable when semen analysis is abnormal or when pregnancy has not been achieved after six to twelve months of attempts.
Lifestyle remains foundational. Weight loss of five to ten percent in men with obesity can raise testosterone by roughly two nanomoles per litre, while resistance training and improved sleep hygiene produce smaller but meaningful gains. Smoking cessation and moderation of alcohol also contribute to overall endocrine health.
Lifestyle factors and long-term patient support
Successful long-term management depends on more than prescriptions alone. Men benefit from clear education about expected timeframes for symptomatic improvement, which may take three to six months, and from recognition that mood, libido, and energy often recover at different rates. Engagement with primary care through a chronic disease management plan can subsidise allied health input from exercise physiologists and dietitians registered with Medicare.
Practical resources help sustain motivation. Beyond clinical guidance, activities that support mental wellbeing, including recreational engagement, should be part of broader conversations about quality of life. Local support networks, including those coordinated through Healthy Male and prostate cancer groups in Australian capital cities, offer peer experience that complements medical therapy.
Submit your manuscript to Urological Science and contribute to evidence-based care for men across Australia and the wider Asia-Pacific region.